HOME > BUSINESS > Sun Pharma to get dengue vaccine technology from ICGEB

Sun Pharma to get dengue vaccine technology from ICGEB

iggebPharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.

The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.

A serotype is a serologically distinguishable strain of a microorganism.

Currently, half of the global population lives under dengue threat; and an estimated 390 million infections occur worldwide every year with approx. 100 million cases of clinical disease and over 25,000 deaths. All four dengue virus serotypes are now endemic in India.

Currently, there are no available antivirals, which presents a public health challenge in India and other parts of the world, including developed nations. There is no specific treatment other than supportive clinical care, which is extremely difficult in developing countries with poor resources.

“Our new collaboration with ICGEB for developing an affordable dengue vaccine is part of our programme for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world,” said Kirti Ganorkar, Executive VP & Head, Global Business Development, Sun Pharma.

International Centre for Genetic Engineering and Biotechnology (ICGEB) has developed a dengue vaccine based on a tailored recombinant virus-like-particle (VLP). The vaccine contains host-receptor binding domain of envelope protein of all the four dengue virus serotypes.

According to the agreement signed, ICGEB shall disclose and make available to Sun Pharma all such existing ICGEB know-how as well as effective completion of technology transfer by ICGEB to Sun Pharma within stipulated timeframe. Sun Pharma will fund & support further development of the vaccine candidate and existing ICGEB know-how and patents.

ICGEB will grant Sun Pharma exclusive rights and licenses for development and commercialisation of this vaccine globally and it will receive pre-defined royalty & payments.

The Company has past experience in development of Hep-B and Typhoid vaccines, as well as complex vaccines, such as HPV and Malaria.

Dengue is a neglected mosquito-borne viral disease that is rapidly spreading globally. Dengue incidence has increased by more than 30-fold in the past 50 years.

The Sun Pharma – ICGEB dengue vaccine candidate is expected to provide a competitive edge over others in all three critical parameters of Safety, Efficacy & Affordability that define an ideal dengue vaccine.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.

“The immediate priority of this partnership is to complete the Toxicology studies for further development of the program,” Sun Pharma said.

This is the second collaboration between Sun Pharma and ICGEB focusing on dengue.

The first one announced in May 2016 was related to the development of a botanical drug for treatment of Dengue. The current collaboration is focussed on developing a safe & effective vaccine for the prevention of dengue.

Initial findings of ICGEB’s dengue vaccine indicate that the candidate induces serotype specific non-cross-reactive and strongly neutralizing antibodies without disease enhancing concerns.

These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programs that are developed or in development globally.

This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population.

Dr Salunke, Director – International Centre for Genetic Engineering and Biotechnology (ICGEB) said, “Despite recent approval of a dengue vaccine and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious dengue vaccine still faces major challenges. Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations.”

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and one of India’s largest pharmaceutical company.

It provides affordable medicines in over 150 countries across the world.

Sun Pharma’s global presence is supported by 47 manufacturing facilities spread across 6 continents. The consolidated revenues for 12 months ending March 2016 are approximately U$ 4.3 billion.

It has 32 brands and 14 API manufacturing facilities across the globe.

The International Centre for Genetic Engineering and Biotechnology is an international, non-profit research organization.

The ICGEB provides a scientific and educational environment and conducts innovative research in life sciences for the benefit of developing countries. It strengthens the research capability of its Members through training and funding programmes and advisory services and promotes biotechnology internationally.

The Centre is dedicated to advanced research and training in molecular biology and biotechnology and applies the latest techniques in the fields of biomedicine, crop improvement, environmental protection/remediation, biopharmaceuticals and biopesticide production.

Follow ULTRA.news
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...
Royal Orchid Hotels inks marketing tie-up with UK’s Bespoke Hotels Royal Orchid Hotels said it had tied up with Bespoke Hotels of the UK to market each others' properties to their customers.Bespoke manages over 200 hots with 9,500 hotel rooms, 8,000 employees and £815 million of assets."Royal Orchid now has the ability to offer its gues...
Alembic Pharma buys US-based generics manufacturer Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.Orbit has "a team of eight highly experienced scientists," Alembic said, adding that the firm focuses ...
Lupin Q2 sales down 8%, PAT falls 31.3% Pharma major Lupin reported an 8% fall in Q2 revenue to Rs. 3,952 cr.Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter fell by 13% to 927 cr.Net profit was also down by 31.3% at Rs 455 cr in in the September quarter. The profit was high...
Cipla gets USFDA nod to launch kidney drug in the US Pharma giant Cipla said it received final approval to market a generic version of Genzyme’s kidney drug Renvela Tablets in the US.Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health.The approval...
Suven Life Sciences gets patent for neuro drug Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for "a class of selective 5-HT4 compounds" that are being developed to treat neurodegenerative diseases.The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficie...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon.The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...
NATCO Pharma to sell multiple sclerosis drug in USA via Mylan NATCO Pharma Limited said it the US Food and Drug Administration approved the generic drug application filed by its marketing partner Mylan for injections used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system.The drug, Glat...
Cyient ties up with US start-up to incorporate AI tech in power solution Mumbai-based IT services provider Cyient said it has signed an agreement to incorporate machine learning meter and voltage signature technology from US-based startup Elpis in its solutions for power utilities."Through this agreement, Cyient and Elpis will jointly pursue util...
Infosys to deliver private cloud solution based on Suse Linux and Openstack IT services provider Infosys said it now offers a private cloud solution built using SUSE Linux and Openstack.The solution will make use of Openstack cloud and datacenter solutions developed by Germany-based Micro Focus SUSE.Infosys and Micro Focus SUSE have jointly inve...
Vivimed pharma unit gets Rs 270 cr investment from OrbiMed fund Pharmaceuticals and specialty chemicals maker Vivimed Labs said investment firm OrbiMed will invest $42.5 mn (Rs 270 cr) into its active pharmaceutical ingredients business.The investment will be into Vivimed Labs Mascarene Ltd, which is in turn the holding entity of the com...
L&T Technology Services to co-develop solutions with Intel unit L&T Technology Services, the engineering services arm of the construction conglomerate, will co-develop industrial solutions with Intel subsidiary Wind River, which works in the emerging domain of Internet of Things.Under the partnership L&T Technology Services will "validat...
Glenmark to launch Desonide topical ointment in US Glenmark Pharmaceuticals Inc said it has got the go-ahead to launch the generic version of Perrigo's anti-inflammation ointment Desonide Ointment in the US.Desonide Ointment, 0.05% had annual sales of approximately $23.4 million for the 12 month period ending July 2017, acco...
Biocon passes US-FDA inspection at Vishakapatanam plant Biocon said the plant inspection conducted by the US Food and Drug Administration at its Vishakapatanam plant passed without incident."US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Wishakhapatnam, Andhra Pradesh from September 11 to 1...
Zydus Cadila gets approval for two drugs in the US Zydus Cadila said it received the final regulatory approval to market anti-sleep drug Modafinil in the US, and tentative approval for bladder control drug Solifenacin Succinate.Unlike a final approval, tentative approvals don't allow the grantee to sell the drugs in the US m...
Uflex develops pack to preserve a sandwich for 8 days in room temperature Uflex, one of the world's largest food packaging manufacturers, said it has developed an 'active' packaging material that can double the unrefrigerated shelf life of food items such as sandwiches."The special properties of the FDA approved packaging material keep the pouch a...
Godrej Properties, Nirmal to co-develop huge project in Thane West Mumbai-based real estate company Godrej Properties said it has signed a joint venture agreement with Nirmal Ventures, also based in Mumbai, for developing a residential project in Thane.The project, located on the Lal Bahadur Shastri (LBS) Marg, Thane West, will be developed...